REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Share News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Swallowfield, Perpetual Income & Growth IT

Mon, 14th Jun 2010 12:22

Shares in Swallowfield, a supplier of cosmetics and toiletries to the own label and branded sectors, dropped after the group warned that trading in the second half will be below expectations.Perpetual Income and Growth Investment Trust's shares produced a total return of 31% to shareholders over the 12 months to 31 March, while the total return of the company's benchmark for performance measuring purposes, the FTSE All-Share Index, was 52.3%. Drug developer Phytopharm has been given the go-ahead for a phase two trial of its Parkinson's disease treatment Cogane by the US Food and Drug Administration. The study will investigate the efficacy, safety and tolerability of Cogane administered for 28 weeks to patients with early stage Parkinson's disease.Nexus Management has issued £175,000 worth of convertible loan notes to the SF t1PS Smaller Companies Growth Fund. Interest is 10% per annum, payable quarterly in arrears. The company has also issued to SF t1ps £200,000 of warrants exercisable until June 2011 at 0.35p per share of which £50,000 will be exercised immediately.The company has also reached an agreement with VPEP, which will accept a total of $335,000 in satisfaction of approximately $525,000 of debt.Executive search firm Gartner said its Norman Broadbent subsidiary is forming a joint venture with Russam GMS. The new company will be called NB: Board Interim and will specialise in the provision of interim board executives.The joint venture will initially focus on capitalising on Norman Broadbent's experience through their Executive Search business in the financial services, public sector and healthcare, engineering, manufacturing and construction, technology and telecoms, and media sectors.East Russia-focused Amur Minerals has found nickel and copper mineralisation in a road cut immediately to the south of the Ikenskoe deposit, the largest of the three drilled deposits within the Kun Manie exploration licence. "This find confirms our belief that Ikenskoe could be substantially larger than presently reported, and our initial expectations are that the mineralisation extends both to the east and south of the known deposits," said boss Robin Young.Uranium Resources has started drilling on its Mtonya prospect in Tanzania, a known uraniferous district which has yielded the Nyota deposit for Mantra Resources.The two-phase drilling programme will comprise approximately 3,000m in two drill fences. Phase 1 will drill 1,500m and complete late July/early August, with Phase 2 carried out between August and October.Akers Biosciences, a maker of diagnostic screening and testing products, has signed a contract with US healthcare distribution group Fisher to supply its PIFA Heparin/PF4 Rapid Assay product, which is used to detect if a patient being treated with the blood thinner Heparin may be developing a drug allergy.
More News
8 Oct 2018 13:10

Akers Biosciences appoints chief executive after settling legal battle

(Sharecast News) - Akers Biosciences appointed Howard Yeaton as chief executive on Monday as the company reached a settlement in its legal dispute with Pulse Health.

Read more
15 Aug 2018 08:04

Akers Biosciences profits hit over antigen difficulties

(Sharecast News) - Akers Biosciences' losses burgeoned as second-quarter revenues were cut in half after softer sales of its flagship Heparin rapid assay products had offset a stronger showing in its breathalyser unit.

Read more
3 Apr 2018 13:45

Akers Biosciences 2017 Revenue Rises But Loss Widens On Higher Costs

LONDON (Alliance News) - Akers Biosciences Inc on Tuesday said revenue grew in 2017, but its loss widened due to increased costs across the business.The AIM-listed firm

Read more
16 Mar 2018 18:11

Akers Biosciences Nets USD49,000 From Warrants Exercise (ALLISS)

LONDON (Alliance News) - Akers Biosciences Inc, a developer of health screening and testing products, said Friday that it has netted USD48,750 from warrants to

Read more
16 Feb 2017 08:44

Akers Biosciences gains US patent for disposable cartridge

(ShareCast News) - Akers Biosciences, a developer of rapid health information technologies, has been granted a US patent for its wellness disposable markers. The US Patent and Trademark Office has given a patent for its proprietary cartridge for the optical scanning device used in the company's Brea

Read more
10 Jan 2017 12:06

Akers Biosciences to raise $2m in US placing

(ShareCast News) - Rapid diagnostic test manufacturer Akers Biosciences said it plans to issue $2m of new shares plus warrants over another $1m worth of shares. The AIM- and Nasdaq-listed outfit said funds will be used for working capital as well as to accelerate growth in the US and in internationa

Read more
19 Dec 2016 14:52

Akers Biosciences signs three year deal with US hospital group

(ShareCast News) - Rapid health information technology developer Akers Biosciences announced on Friday it has signed a three-year agreement with the Greater New York Hospital Association to introduce its flagship rapid tests for heparin-induced thrombocytopenia across the association's network of ov

Read more
12 Dec 2016 16:03

UK Shareholder Meetings Calendar - Next 7 Days

Read more
1 Dec 2016 12:13

Akers Agrees Deal For First Check To Sell Cholesterol Test In US

Read more
10 Nov 2016 09:46

Akers Biosciences gains European patent for ketone breath device

(ShareCast News) - Akers Biosciences, a developer of rapid health information technologies, gains a European patent for its ketone acid breath device. The European Patent Office has issued a patent covering the company's breath ketone detector, a breath device to monitor ketone levels, which follows

Read more
19 Aug 2016 12:18

Akers Biosciences, ChubeWorkx settle lengthy legal dispute

(ShareCast News) - Akers Biosciences has reached a settlement agreement with former distributor ChubeWorkx Guernsey Ltd, allowing it to recover $1.25m in product and cash and end a lengthy legal dispute between the pair. ChubeWorkx would recover what it was owed from a promissory note by taking deli

Read more
18 Aug 2016 07:22

Akers Says Test Results "Highly Successful" For BreathScan OxiChek

Read more
30 Jun 2016 08:56

Akers Says Rapid Chlamydia Test Trial "Highly Successful"

Read more
27 Jun 2016 08:16

Akers Biosciences Signs First Distribution Deal For BreathScan OxiChek

Read more
26 May 2016 16:27

DIRECTOR DEALINGS: Akers Biosciences Chief Executive Buys First Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.